On September 19, more than 100 patients, family members, and guests gathered for a patient education program on current and emerging approaches to diagnosing and managing myeloproliferative neoplasms (MPNs). Hosted by WashU Team MPN, the event featured presentations from WashU Med hematology physicians Stephen Oh, MD, PhD, Amy Zhou, MD, and Helen Ajufo, MD, alongside […]
Researchers at WashU Medicine have identified a possible route to tame inflammation in myeloproliferative neoplasms — a group of chronic blood cancers — that could serve as a novel approach to treatment. The study is led by Stephen Oh, MD, PhD, a professor of medicine who treats these patients at Siteman Cancer Center, based at […]
The NIH has awarded WashU Medicine an $11.7 million grant to study how inflammation drives myeloproliferative neoplasms, a group of blood cancers at high risk of progressing to acute myeloid leukemia. “This funding supports a true team-science effort because all four projects look at inflammation, but each in a different way,” said principal investigator Stephen T. […]
In this study, WashU Researchers discovered how protein homeostasis mechanism, unfolded protein response (UPR) signaling regulates blood cell lineage output. Given that UPR signaling is upregulated in many cancers, this study provides important insights into targeting UPR signaling as therapeutic strategies. Their findings were published in Blood Advances. Choi, H., Jung, S.-E., Earth, Y., Paik, H., […]
This study by WashU Researchers shows that a novel blood-based digital PCR test can detect when treatment is failing a median of three months before standard of care testing identifies treatment failure —enough lead time to change therapy and potentially improve outcomes for these patients. Findings of this study have been published in Haematologica. Noor, A., […]
Recent publications from members of the Division of Hematology at WashU Med, emphasize the ongoing safety challenges of anticoagulant therapies in high-risk patient populations. “The first month after direct oral anticoagulants: a window of vulnerability” (published in Research and Practice in Thrombosis and Haemostasis), is commentary from Amber Afzal, MD, MSCI on direct oral anticoagulants (DOACs). “Anticoagulant […]
We are deeply saddened by the passing of Dr. Katherine Ponder. During her time spent at WashU Hematology, she was a pioneering expert in gene therapy whose research advanced the treatment of hemophilia. Her decades of scientific research made a profound, lasting impact on both patient care and the broader research community. Dr. Ponder will be greatly missed as an esteemed colleague and friend.